Skip to main content

Athersys is a 'very different company' from a year ago, CEO says

In June 2022, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while completing the testing and commercialization of its adult stem-cell therapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.